Warning: The NCBI web site requires JavaScript to function. more...
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM, Tari AM.
Breast Cancer Res. 2008;10(3):R44. Epub 2008 May 12.
Related citations
JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM.
Int J Oncol. 2011 Apr;38(4):963-71. doi: 10.3892/ijo.2011.925. Epub 2011 Jan 25.
Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, Perantoni AO.
Oncogene. 2009 Jan 29;28(4):619-24. Epub 2008 Nov 3.
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK.
Mol Cancer Ther. 2003 Apr;2(4):409-17.
Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J, Li C, Qu W, Leslie E, Bonifant CL, Buzard GS, Saavedra JE, Keefer LK, Waalkes MP.
Mol Cancer Ther. 2004 Jun;3(6):709-14.
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.
Breast Cancer Res. 2007;9(6):R76.
Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK, Saavedra JE.
Bioorg Med Chem. 2008 Nov 15;16(22):9764-71. Epub 2008 Sep 30.
Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.
Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G.
Clin Exp Metastasis. 2000;18(2):171-8.
3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases.
Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI.
BMC Cancer. 2006 Mar 21;6:77.
Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
Ramer R, Hinz B.
J Natl Cancer Inst. 2008 Jan 2;100(1):59-69. Epub 2007 Dec 25.
Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells.
Ramer R, Eichele K, Hinz B.
Oncogene. 2007 Aug 23;26(39):5822-7. Epub 2007 Mar 19.
The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE, Saavedra JE, Chakrapani H.
Anticancer Agents Med Chem. 2009 Sep;9(7):798-803. Epub 2009 Sep 1. Review.
In vitro irradiation of basement membrane enhances the invasiveness of breast cancer cells.
Paquette B, Baptiste C, Therriault H, Arguin G, Plouffe B, Lemay R.
Br J Cancer. 2007 Dec 3;97(11):1505-12. Epub 2007 Nov 6.
Cobalt chloride-induced hypoxia modulates the invasive potential and matrix metalloproteinases of primary and metastatic breast cancer cells.
Fu OY, Hou MF, Yang SF, Huang SC, Lee WY.
Anticancer Res. 2009 Aug;29(8):3131-8.
Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC.
BMC Cancer. 2009 Jan 14;9:20.
Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer.
Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J.
BMC Cancer. 2009 Jul 14;9:230.
Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
Shami PJ, Saavedra JE, Bonifant CL, Chu J, Udupi V, Malaviya S, Carr BI, Kar S, Wang M, Jia L, Ji X, Keefer LK.
J Med Chem. 2006 Jul 13;49(14):4356-66.
Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179.
Waleh NS, Murphy BJ, Zaveri NT.
Cancer Lett. 2010 Mar 1;289(1):111-8. Epub 2009 Sep 13.
Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors.
Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK.
Int J Oncol. 2005 Apr;26(4):1101-9.
Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer.
Lee YK, So IS, Lee SC, Lee JH, Lee CW, Kim WM, Park MK, Lee ST, Park DY, Shin DY, Park CU, Kim YS.
J Gene Med. 2005 Feb;7(2):145-57.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on